Streptococcal infection

This first-in-human trial tests a new vaccine designed to protect against Group A Streptococcus (Strep A), a bacteria that can cause sore throats, skin infections, and more serious illnesses. Healthy adults aged 18 to 25 will receive one of two vaccine formulations, each with a d…

This study tests a new pneumococcal vaccine in about 2400 healthy infants starting at 2 months old. The goal is to see if the new vaccine is as safe as the current vaccine, Prevnar 20, and if it can protect against more types of bacteria that cause pneumonia, meningitis, and ear …

This trial evaluates an experimental vaccine called 20vPnC, designed to protect against 20 types of pneumococcal bacteria. Healthy infants aged 42 to 98 days will receive either 20vPnC or the approved 13vPnC vaccine at 2, 4, 6, and 12-15 months. The study aims to compare safety a…

This study tests a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. The trial includes 854 healthy people aged 2 months and older, split into two phases to check safety and immune respons…

This early-stage study tests a new pneumococcal vaccine booster in 45 toddlers aged 12-15 months who already received their routine pneumonia shots. The goal is to check for side effects like tenderness, fever, and sleepiness. The study compares the new vaccine to an existing one…

This early-stage study is testing a new vaccine called V118E to see if it is safe and well-tolerated in healthy adults. The vaccine aims to protect against infections caused by Streptococcus pneumoniae bacteria, which can cause pneumonia and other serious illnesses. Around 126 he…

This study tests a new pneumococcal vaccine in healthy infants to see if it is safe and works better than the current vaccine. About 3,230 babies will receive either the new vaccine or the existing one at routine checkups. Researchers will compare side effects and immune response…

This study tests a vaccine given to pregnant women to see if it can protect their babies from group B streptococcus (GBS) infection, a serious illness in newborns. Healthy pregnant women aged 49 or younger, between 24 and 36 weeks of pregnancy, can join. Participants receive one …

This study tests a new pneumococcal vaccine (PG4) in healthy children aged 15 months to 18 years. About 1,200 participants will receive either the new vaccine or the current Prevnar 20. Researchers will compare safety and immune response over 6 months. The goal is to see if the n…

This study tests whether two different pneumococcal vaccines can create antibodies that kill newly discovered types of pneumonia bacteria. Researchers will give healthy adults one of the vaccines and measure how well their immune system fights these bacteria. The goal is to see i…

This early-stage trial tests a new vaccine called VAX-A1 in 80 healthy adults aged 18-40. The vaccine aims to prevent infections caused by Group A Streptococcus bacteria, which can cause strep throat and more serious illnesses. The study focuses on safety and immune response, wit…

This early-stage trial is testing a new vaccine called V118C to prevent pneumococcal disease, which can cause serious lung and other infections. About 210 toddlers and infants will receive either V118C or an existing vaccine to compare safety and immune response. The study is cur…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children and teens with sickle cell disease, aged 2 to 17. The goal is to see if it's safe and helps the body make antibodies better than the current 20-valent vaccine. Participants get one shot and are monitore…

This study tests whether a two-shot pneumonia vaccine series (PCV20 and PPSV23) can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 adults with CLL who have not yet had treatment, or who are on a specif…

This study looks at whether giving the 20-valent pneumococcal vaccine (PCV-20) to adults while they have a fever is as effective and safe as waiting until they are well. About 1052 adults with certain health risks (like heart or lung disease) will take part. The goal is to see if…

This study is checking how safe the Prevenar 20 vaccine is once it's used in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will get one dose. Researchers will track any side effects for 28 days after vaccination.

This Phase 3 trial is testing a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response compared to an existing vaccine. If it works, i…

This study tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. Around 180 healthy children will receive either the new vaccine or an existing one …

This study tests a new vaccine called PCV24 in 420 healthy children aged 2 months to 5 years. The vaccine targets 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. Researchers will compare it to an existing vaccine to see if it is safe …

This early-stage study will give 12 healthy adults a killed whole-cell pneumococcal vaccine called Gamma-PN. The main goal is to collect blood samples to help develop and validate lab tests that measure immune responses. The study does not aim to prove the vaccine works in people…

This study compares two pneumococcal vaccination strategies in 160 adults with lymphoma who have had chemotherapy. One group gets two vaccines (Prevenar 13 followed by Pneumovax 23), while the other gets a single newer vaccine (Prevenar 20). Researchers will measure immune respon…

This study looks at whether the antibiotic clindamycin works as well as other drugs for treating Streptococcus infections in artificial joints. Researchers will compare success rates in 260 adults who had surgery for this infection. The goal is to see if clindamycin can be a good…

People without a working spleen are at high risk of severe infections from pneumococcus bacteria. This study looks at how well the pneumococcal vaccine works in adults aged 18-65 who have a spleen injury and are treated with monitoring, embolization, or spleen removal. Researcher…

This study tests a new device that uses artificial intelligence to help diagnose ear infections, strep throat, and asthma flare-ups in children. About 84 kids aged 3 to 17 will either use the device at home with a doctor's video visit or receive standard in-person care. The goal …

This study tests a new vaccine (PCV21) designed to protect babies against 21 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 2,200 healthy infants will receive four doses of either the new vaccine or an existing one starting at 2 mont…

This study prepares medical sites in Kenya, Malawi, Mozambique, and Uganda for future trials of a vaccine against Group B Streptococcus (GBS), a leading cause of serious infections in newborns. Researchers will track pregnancy and infant health data and monitor GBS cases in babie…

This study collects blood from 50 women in Uganda who previously received an experimental group B strep (GBS) vaccine during pregnancy. The blood is used to create quality control panels that help labs accurately measure vaccine-induced antibodies. The goal is to improve testing …

This study is observing 2,500 children in France to understand how pneumococcal vaccines have changed the severity and types of pneumococcal infections. Researchers will look at which bacterial strains cause disease, how severe the infections are, and whether children were vaccin…

This study looks at how a type of immune cell called neutrophils affects the body's response to the pneumococcal vaccine in young (21-40) and older (65+) adults. Researchers will measure how well neutrophils kill pneumonia bacteria after vaccination. The goal is to understand why…

This study looks at children ages 5 to 15 who test positive for strep throat to understand why some become carriers—meaning they have the bacteria but no symptoms. Researchers will collect throat samples and analyze gene activity to compare carriers with those who have active inf…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study is looking back at medical records of 400 adults hospitalized with a serious strep blood infection (Streptococcus anginosus group). The goal is to find out which factors are linked to a higher chance of dying within 28 days. By understanding these risk factors, doctors…

This study looks at how families feel about antibiotic use and whether a Garmin smartwatch can track symptoms in children aged 4-17 with common infections like UTIs, tonsillitis, or skin infections. About 300 children from the Royal Children's Hospital Emergency Department will w…